title: Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
authors.forename: S
authors.initials: S
authors.lastname: Bracarda
authors.forename: R
authors.initials: R
authors.lastname: Iacovelli
authors.forename: L
authors.initials: L
authors.lastname: Boni
authors.forename: M
authors.initials: M
authors.lastname: Rizzo
authors.forename: L
authors.initials: L
authors.lastname: Derosa
authors.forename: M
authors.initials: M
authors.lastname: Rossi
authors.forename: L
authors.initials: L
authors.lastname: Galli
authors.forename: G
authors.initials: G
authors.lastname: Procopio
authors.forename: M
authors.initials: M
authors.lastname: Sisani
authors.forename: F
authors.initials: F
authors.lastname: Longo
authors.forename: M
authors.initials: M
authors.lastname: Santoni
authors.forename: F
authors.initials: F
authors.lastname: Morelli
authors.forename: G
authors.initials: G
authors.lastname: Di Lorenzo
authors.forename: A
authors.initials: A
authors.lastname: Altavilla
authors.forename: C
authors.initials: C
authors.lastname: Porta
authors.forename: A
authors.initials: A
authors.lastname: Camerini
authors.forename: B
authors.initials: B
authors.lastname: Escudier